BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©The Author(s) 2026.
World J Gastrointest Surg. Jan 27, 2026; 18(1): 112334
Published online Jan 27, 2026. doi: 10.4240/wjgs.v18.i1.112334
Table 5 Comparison of treatment measures between two groups, n (%)
Indicators
Intolerance group (n = 76)
Tolerance group (n = 119)
Test statistic
P value
Respiratory support
Mechanical ventilation68 (89.5)88 (73.9)6.2980.012
PEEP (cmH2O), mean ± SD8.4 ± 2.67.2 ± 2.13.4680.001
FiO2 (%), mean ± SD52.4 ± 18.242.8 ± 14.64.227< 0.001
Circulatory support
Vasoactive drug use60 (78.9)70 (58.8)7.9410.005
Vasoactive drug duration (day), mean ± SD8.6 ± 4.25.9 ± 3.14.873< 0.001
Gastrointestinal therapy
Gastrointestinal motility drug use68 (89.5)70 (58.8)19.586< 0.001
Other therapies
Antibiotic therapy duration (day), mean ± SD14.8 ± 6.211.2 ± 4.84.284< 0.001
Continuous renal replacement therapy32 (42.1)31 (26.1)5.2590.022
Surgical intervention28 (36.8)31 (26.1)2.4720.116


Write to the Help Desk